AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Blood test guides custom ALS supplements in new pilot study
Disease control CompletedThis study tested a new approach to treating ALS by using a blood test to sort people into four disease categories. Based on their category, participants received a specific supplement for six months. The goal was to see if these personalized supplements could slow down the progr…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Can this drug slow ALS? new study results are in
Disease control CompletedThis study tested a drug called MCI-186 in 206 people with ALS, a disease that weakens muscles over time. The goal was to see if the drug could slow down the disease better than a placebo (a dummy treatment) over 24 weeks. Researchers measured changes in patients' ability to do d…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 26, 2026 03:48 UTC
-
New drug shows promise in slowing ALS progression?
Disease control CompletedThis study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III). The goal was to see if daily intravenous doses could slow the decline in daily function over 24 weeks compared to a placebo. The trial was exploratory, meaning it looked for signals of ef…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New ALS drug shows promise in slowing disease progression
Disease control CompletedThis study tested a drug called MCI-186 in 137 people with ALS, a disease that weakens muscles over time. The goal was to see if the drug could slow down the loss of muscle function compared to a placebo over 24 weeks. Participants received daily infusions of the drug or a dummy …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
ALS drug edaravone tested for Long-Term safety in 124 patients
Disease control CompletedThis study looked at the long-term safety of an oral form of edaravone in 124 people with ALS over 96 weeks. ALS is a progressive nerve disease that weakens muscles. The main goal was to see how safe and tolerable the drug is when taken for a long time, not to cure the disease. P…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
ALS drug shows promise in slowing disease
Disease control CompletedThis study tested a drug called MCI-186 (edaravone) in 181 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease and keep patients functioning longer. Participants received either the drug or a placebo…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 15, 2026 11:57 UTC